A pioneering prescription refill program in Utah, launched without much fanfare, is now at the center of a heated debate. The use of artificial intelligence to perform tasks traditionally reserved for doctors raises significant questions about the future role of AI in healthcare.
The Program and Its Implications
The new program allows residents in Utah to refill their prescriptions online through an AI chatbot named Doctronic. This development is seen as a step towards increased convenience in healthcare for both patients and prescribers. However, it also sets a new precedent, sparking concerns among doctors, legal experts, and public health professionals.
Current state and federal laws limit prescription authority to licensed medical professionals. Proponents of the program argue that these laws need to be updated to accommodate AI technologies. However, many experts, including Dr. Eric Bressman from the University of Pennsylvania, emphasize the need for AI to meet the same rigorous standards as human doctors.
Regulatory Challenges and Oversight
Utah’s initiative succeeded by creating a “regulatory sandbox,” which allows certain legal waivers for AI companies demonstrating promising technology. The refill program operates under the supervision of a five-member board of AI specialists, who are not physicians. Initially, human doctors oversee all refill orders from Doctronic, with plans to move to full automation.
The state’s medical licensing board was taken by surprise by this program. Dr. Alan Smith, a family physician leading the board, expressed concerns over the risks of automatic prescription renewals without thorough medical evaluations.
The regulation of medical technology remains a complex issue, with the federal government typically overseeing impacts on medical care. Yet, the boundary of AI’s role remains a contentious point.
AI in Healthcare Across the U.S.
Doctronic’s executives remain focused on patient needs rather than regulatory hurdles. Patients can access the refill service through a dedicated website, where the AI verifies prescriptions against a national pharmacy database. For complex requests, the system involves telehealth doctors.
Envisioning a broad scope, Dr. Adam Oskowitz, a co-founder of Doctronic, anticipates that many routine tasks, such as ordering tests, could be handled by AI in the future.
Other states, including Texas and Wyoming, have begun easing rules to enable AI in healthcare, while legislators in Iowa and Idaho look to formally integrate AI into medical services. This legislative push often draws from templates by pro-AI entities like the Cicero Institute.
Concerns and Safety
Critics, like Dr. Smith, cite real patient risks due to potential changes in a patient’s medical history that could render a once-appropriate prescription hazardous. The American Medical Association and others echo these safety concerns, indicating the complex nature of prescription renewals.
In response, some drugs have been removed from Doctronic’s refillable list. Initial data on the program has been shared, and more comprehensive studies are planned, despite current publications lacking independent review.
Federal Oversight and Future Prospects
Despite the pressures, the FDA has not authorized any medical-purpose AI chatbots. The agency emphasizes its commitment to safety while encouraging innovation. Daniel Aaron from the University of Utah highlights the risk that companies might expand prematurely, potentially undermining public trust.
Artificial intelligence in healthcare remains a subject of significant debate and cautious optimism as companies navigate varying state regulations.
The Associated Press Health and Science Department maintains responsibility for its content, with support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation.